ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2648

Characterization Of Histidyl-tRNA Synthetase Specific Th Cell Response In Blood and Broncheoalveolar Lavage (BAL) Of Myositis Patients

Inka Albrecht1, Eddie James2, Maryam Fathi3, Maryam Dastmalchi4, Jessica Herrath1, Vivianne Malmström5 and Ingrid E. Lundberg6, 1Department of Medicine, Solna, Unit of Rheumatology, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, 2Benaroya Research Institute, Seattle, WA, 3Karolinska Institutet, Department of Medicine , Respiratory Medicine Unit, Stockholm, Sweden, 4Department of Medicine, Karolinska University Hospital, Department of Medicine, Solna, Unit of Rheumatology, Stockholm, Sweden, 5Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 6Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: T cells and myositis

  • Tweet
  • Email
  • Print
Session Information

Title: ACR Plenary Session III: Discovery 2013

Session Type: Plenary Sessions

Background/Purpose:

 Idiopathic inflammatory myopathy is a rare chronic inflammatory disease that is associated with the presence of autoantibodies pointing to a contribution of adaptive immune responses to disease manifestation. One of the most frequent myositis-specific autoantibodies is raised against histidyl-tRNA synthetase (Jo1). This autoantibody can be detected in 20% of myositis patients and is associated with interstitial lung disease (ILD). ILD may precede myositis symptoms implicating that the autoimmune reaction may start in the lungs. The release of Jo1 and fragments thereof into the extracellular milieu is believed to trigger both activation of T cells by antigen-presenting cells and influx of CCR5 expressing cells e.g. dendritic cells and Th1 lymphocytes. So far, there is only limited knowledge about Jo1-reactive T cells in myositis patients.

Methods:

A candidate T cell epitope was predicted from the N-terminal part of the Jo-1 protein. In order to identify and characterize Jo1 antigen-specific Th cells, we stimulated peripheral blood (n=9) and BAL cells (n=3) of myositis patients with either recombinant Jo1 protein or the 13aa peptide covering the predicted epitope. Subsequently, CD3+CD4+T cells were analyzed for up-regulation of CD40L by flow cytometry at day 5. In addition, T cells were examined for effector functions by measuring expression of intracellular cytokines. Finally we compared the phenotype of T cells in blood and BAL (n=4) by staining for Th1 associated chemokine receptors.

Results:

Stimulation of cells from blood and BAL with Jo1 protein caused a high up-regulation of CD40L on CD3+CD4+ T cells. Thus, Jo1-specific CD4+T cells can be detected in both blood and BAL fluid of myositis patients. Upon activation, Jo1-specific T cells mainly show Th1 effector functions as evident by IFNg expression.

Stimulation of cells with the 13aa peptide corresponding to our novel candidate T cell epitope also resulted in a high up-regulation of CD40L.

Moreover, Jo1-reactive T cells are highly enriched in the BAL fluid. Those antigen-specific T cells have a highly pronounced Th1 phenotype as around 60% produce IFNg in response to antigen stimulation compared to only 10% IFNg responders in the corresponding blood samples. Interestingly, BAL T cells were all (100%) positive for CXCR3 and CCR5, two chemokine receptors specifically expressed on Th1 cells. In contrast, CD4+T cells derived from blood only showed 20% positivity for CCR5 and CXCR3 expression, respectively.

Conclusion:

 In this study, we were able to demonstrate presence of Jo1-reactive CD4+ T cells in inflammatory myopathies and thus provide evidence that those T cells do react with epitopes on this autoantigen. Jo1 reactive CD4+ T cells are also present in the lung and show here pronounced Th1 effector functions. Moreover, we were able to identify a novel T cell epitope of the histidyl-tRNA synthetase. This will open up new ways for studying disease mechanisms and might provide novel starting points for therapeutic intervention.


Disclosure:

I. Albrecht,
None;

E. James,
None;

M. Fathi,
None;

M. Dastmalchi,
None;

J. Herrath,
None;

V. Malmström,
None;

I. E. Lundberg,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-histidyl-trna-synthetase-specific-th-cell-response-in-blood-and-broncheoalveolar-lavage-bal-of-myositis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology